Furthermore, the data from TCGA database revealed that HCC patients with higher co-expression of METTL3 and SLC2A1-DT, SLC2A1-DT and β-catenin, SLC2A1-DT and c-Myc, SLC2A1-DT and SLC2A1, SLC2A1-DT and LDHA, as well as SLC2A1-DT and HK2 had worse prognosis (Fig. 8D, Fig. S8B). This evidence concerns the gene METTL3 and hepatocellular carcinoma.